Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Shareholders include Third Rock Ventures, Fidelity, Nextech Invest, Wellington Management, Casdin Capital, Cowen Investments, Partner Fund Management, Perceptive Advisors, RA Capital Management, Redmile Group, Sabby Capital, Tavistock Life Sciences.
The Cambridge, MA-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol BPMC. Blueprint Medicines initially filed confidentially on February 19, 2015. Goldman Sachs and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
